Patient Derived Xenografts for Breast Cancer

Overseen By Clinical Trials Referral Office

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Mayo Clinic

Must be taking: Neoadjuvant therapy

Disqualifiers: Ineligible for surgery, prior malignancy, others

Stay on Your Current Meds You can continue your current medications while participating

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

100 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to help breast cancer patients by creating patient-derived xenografts (PDX), models that study cancer more effectively. The focus is on patients who have undergone pre-surgery therapy (either chemotherapy or hormone therapy) but still have cancer remaining in their breasts, increasing their risk of future health problems. Suitable candidates for this trial include those who received this type of therapy, still have cancer visible in medical imaging, or had to stop therapy because the cancer worsened. Participants must be willing to provide blood and tissue samples for future research. As a Phase 2 trial, this research measures how well the treatment works in an initial, smaller group of people.

Why are researchers excited about this trial?

Researchers are excited about developing Patient Derived Xenografts (PDX) for breast cancer because this approach offers a personalized way to study and treat the disease. Unlike standard treatments such as chemotherapy or hormone therapy, PDX involves implanting a patient's own tumor cells into mice to create a model that mirrors the individual's cancer. This allows for the testing of various therapies in a living system that closely resembles the patient's unique cancer, potentially leading to more effective and tailored treatment plans. By targeting the specific characteristics of each patient's cancer, PDX models could revolutionize precision medicine in breast cancer treatment.

Who Is on the Research Team?

Judy C. Boughey, M.D.

Principal Investigator

Mayo Clinic

Matthew P. Goetz, M.D.

Principal Investigator

Mayo Clinic

Are You a Good Fit for This Trial?

Inclusion Criteria

Diagnosis of invasive breast cancer treated with neoadjuvant systemic therapy.

Surgically resectable disease following neoadjuvant systemic treatment.

Received at least 4 weeks of neoadjuvant endocrine therapy with minimal or no decrease in tumor size by MRI, US or physical examination at discontinuation/completion of neoadjuvant endocrine therapy

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Sample Collection

Collection of blood and leftover surgical tissue from patients with residual breast cancer after chemotherapy or endocrine therapy

1 week

1 visit (in-person)

Laboratory Analysis

Tissue and blood samples are used to grow cancer in the lab and analyze biomarkers

Ongoing

Follow-up

Participants are monitored for safety and effectiveness after sample collection

4 weeks

What Are the Treatments Tested in This Trial?

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials

3,427

Recruited

3,221,000+